Iodide

Iodide

SCHEMBL5050443

C[N+]12CCC(CC1)CC2.[I-]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.93

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6382415 0.93 CHRNA7 (0.93) CHRNA7
SCHEMBL10884827 0.93 CHRNA7 (0.93) CHRNA7
SCHEMBL10884820 0.93 CHRNA7 (0.93) CHRNA7
Water SCHEMBL9979643 0.93 CHRNA7 (0.93) CHRNA7
Bromide SCHEMBL11250560 0.82 CHRNA7 (0.72) CHRNA7
Bicarbonate SCHEMBL3621286 0.80 CHRNA7 (0.68) CHRNA7
Bicarbonate SCHEMBL3621287 0.78 CHRNA7 (0.65) CHRNA7
Bromide SCHEMBL11577972 0.73
SCHEMBL13429190 0.67
SCHEMBL3391562 0.66 CHRNA7 (0.50) CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3009400-B1 NU-3 LEV-TYPE ZEOLITE AND PRODUCTION METHOD THEREFOR TOSOH CORP (JP) 2022-11-30 EP disclosed
US-7361668-B2 Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors UCB, S.A. (BE) 2008-04-22 US disclosed
US-20050020660-A1 Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors UCB, S.A. (BE) 2005-01-27 US disclosed
EP-0040015-B1 PROCESS FOR MAKING OLEFINS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-06-11 EP disclosed
EP-0040016-B1 ZEOLITE NU-3 IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-09-12 EP disclosed
US-4372930-A Zeolite Nu-3 IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1983-02-08 US disclosed
US-4361715-A CATALYZED BY ZEOLITE NU-3 IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1982-11-30 US disclosed
US-4338118-A OF COTTON WITH BICYCLIC QUATERNARY AMMONIUM SALTS ELI LILLY AND COMPANY (US) 1982-07-06 US disclosed
EP-0040015-A1 Process for making olefins IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1981-11-18 EP disclosed
EP-0040016-A1 Zeolite Nu-3 IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1981-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020660-A1 Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors CHRM2, CHRM3, CHRM1 CHRNA7 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.